Camurus ABCAMRF -3.57%79 Gross Margin % is 93.03% as of Mar. 2026, which is 2% above its 10-year median of 91.19. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 738 Biotechnology companies, Camurus AB ranks better than 90.11% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Camurus AB's Gross Profit for the
three
months ended in Mar. 2026 was $53.2 Mil. Camurus AB's Revenue for the
three
months ended in Mar. 2026 was $57.2 Mil. Therefore, Camurus AB's Gross Margin % for the quarter that ended in Mar. 2026 was 93.03%.
The historical rank and industry rank for Camurus AB's Gross Margin % or its related term are showing as below:
CAMRF'
s Gross Margin % Range Over the Past 10 Years
Min: 77.95 Med: 91.19 Max: 98.12
Current: 93.13
During the past 13 years, the highestGross Margin % of Camurus AB was 98.12%. The lowest was 77.95%. And the median was 91.19%.
CAMRF's Gross Margin % is ranked better than 90.11% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs CAMRF: 93.13
Camurus AB had a gross margin of 93.03% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Camurus AB was 1.40% per year.
Camurus AB (OTCPK:CAMRF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Camurus AB had a gross margin of 93.03% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Camurus AB Gross Margin % Related Terms
Camurus AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Camurus AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Camurus AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Camurus AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Camurus AB (CAMRF) has a Gross Margin % of 93.03% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Camurus AB and its competitors. This is near median its historical median of 91.19. Over the past decade, Camurus AB's Gross Margin % has ranged from 77.95 to 98.12. According to the industry distribution chart, Camurus AB ranks #73 out of 738 companies in the Biotechnology industry, placing it in the top 9.9%.
Is Camurus AB's Gross Margin % too high?
Camurus AB's current Gross Margin % of 93.03% is near median its 10-year median of 91.19. Over the past 10 years, this metric has ranged from a low of 77.95 to a high of 98.12. The Biotechnology industry median Gross Margin % is 60.94. Camurus AB's value of 93.03% is 52.7% above this industry median. Based on the distribution chart, Camurus AB ranks #73 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #73 out of 738 companies for Gross Margin %. This places Camurus AB in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Camurus AB's value of 93.03% is 52.7% above this benchmark. Historically, Camurus AB's own Gross Margin % has ranged from 77.95 to 98.12 over the past decade. While the company's 10-year median is 91.19 vs. the industry median of 60.94, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Gross Margin % of 93.03% is 52.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Gross Margin % is 93.03%, which is near median its own 10-year median of 91.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Gross Margin % is 93.03%, which is near median its 10-year median of 91.19 and 52.7% above the Biotechnology industry median of 60.94. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Gross Margin % is 93.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Gross Margin %: 93.03% (near median its 10-year median of 91.19)
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 52.7% above the Biotechnology median (#73 of 738)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
